Related Experiment Video
Updated: Sep 17, 2025
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
Recent advances in cardiovascular disease research driven by metabolomics technologies in the context of systems
Boyao Zhang1, Thierry Schmidlin2
1Institute of Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Insights
Metabolomics, using advanced technologies, offers a powerful approach to uncover new cardiovascular disease (CVD) biomarkers and understand drug interactions for personalized medicine.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- Traditional cardiovascular disease (CVD) risk factors are well-established but lack sophisticated stratification and reliable treatment prediction.
- A deeper understanding of molecular mechanisms is crucial for advancing CVD research and personalized medicine.
Purpose of the Study:
- To review the role of metabolomics in cardiovascular disease (CVD) research.
- To highlight the application of metabolomics in identifying novel biomarkers, pathways, and drug interactions for personalized CVD treatment.
Main Methods:
- Utilizing advancements in Nuclear Magnetic Resonance (NMR) and Ultra-Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) technologies.
- Employing high-throughput, robust, and quantitative characterization of metabolic profiles from various biospecimens.
Main Results:
- Metabolomics enables both targeted and untargeted identification of novel biomarkers and biochemical pathways.
- Applications include tracing drug pharmacokinetics and understanding drug-drug interactions for personalized medication.
Conclusions:
- Metabolomics provides systematic insights into molecular mechanisms underlying CVD.
- This approach enhances CVD risk factor stratification and treatment outcome prediction, paving the way for personalized cardiovascular medicine.
Abstract:
Traditional risk factors and biomarkers of cardiovascular diseases (CVD) have been mainly discovered through clinical observations. Nevertheless, there is still a gap in knowledge in more sophisticated CVD risk factor stratification and more reliable treatment outcome prediction, highlighting the need for a more comprehensive understanding of disease mechanisms at the molecular level. This need has been addressed by integrating information derived from multiomics studies, which provides systematic insights into the different layers of the central dogma in molecular biology. With the advancement of technologies such as NMR and UPLC-MS, metabolomics have become a powerhouse in pharmaceutical and clinical research for high-throughput, robust, quantitative characterisation of metabolic profiles in various types of biospecimens. In this review, we highlight the versatile value of metabolomics spanning from targeted and untargeted identification of novel biomarkers and biochemical pathways, to tracing drug pharmacokinetics and drug-drug interactions for more personalised medication in CVD research (Fig. 1).
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Coronary Artery Disease I: Introduction
00:52What is Metabolism?